Annual Report & AGM Notice

Poolbeg Pharma PLC

09 May 2024

 

Poolbeg Pharma plc 

Annual Report & AGM Notice 

9 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, confirms that the Company's Annual Report and Accounts for the period ended 31 December 2023 and the notice of Annual General Meeting ("AGM") will be posted to shareholders today.

The 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website: https://www.poolbegpharma.com/     

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 13 June 2024 at 2pm. 

Enquiries 

Poolbeg Pharma Plc  Jeremy Skillington, CEO  Ian O'Connell, CFO	[phone]
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)  Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)	[phone]
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)	[phone]
J&E Davy (Joint Broker)  Anthony Farrell, Niall Gilchrist	[phone]
Optimum Strategic Communications  Nick Bastin, Vici Rabbetts, Elena Bates	[phone]  [e-mail]

About Poolbeg Pharma 

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal. 

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma. 

 

END